GORMAN KEVIN CHARLES 4
4 · NEUROCRINE BIOSCIENCES INC · Filed Feb 3, 2026
Research Summary
AI-generated summary of this filing
Neurocrine (NBIX) Director Kevin Gorman Receives 2,297 Shares via RSU Vesting
What Happened Kevin Charles Gorman, a director of Neurocrine Biosciences (NBIX), had 5,142 restricted stock units (RSUs vest) on January 31, 2026. Those RSUs converted to 5,142 shares (reported as derivative exercise/conversion). To satisfy tax withholding, 2,845 of those shares were withheld by the company at an implied price of $136.06 per share, totaling $387,091; no open‑market sale occurred. Net shares issued to Gorman from this vesting were 2,297 shares.
Key Details
- Transaction date: January 31, 2026; Form 4 filed February 3, 2026 (appears timely).
- Vesting: 5,142 RSUs vested on 1/31/2026 (each RSU = 1 share).
- Tax withholding: 2,845 shares withheld at $136.06/share = $387,091 (no shares sold).
- Net shares received: 2,297 shares added to insider holdings.
- Reported holdings: 516,893 shares held by the Gorman and Blais Family Trust, over which Dr. Gorman has voting and investment power.
- Transaction codes: M = exercise/conversion of derivative (RSU to shares); F = shares withheld for tax withholding.
Context This was an RSU vesting event, not an open‑market sale or purchase. The conversion of RSUs to shares with company withholding to pay taxes is a routine administrative action and does not, by itself, indicate a buy or sell decision. The filing shows prior annual vesting of similar RSU tranches (5,141 shares vested in each of 2023–2025 and 5,142 in 2026).
Insider Transaction Report
- Exercise/Conversion
Common Stock
2026-01-31+5,142→ 519,738 total - Tax Payment
Common Stock
[F1][F2]2026-01-31$136.06/sh−2,845$387,091→ 516,893 total - Exercise/Conversion
Restricted Stock Unit
[F3][F4]2026-01-31−5,142→ 0 total→ Common Stock (5,142 underlying)
Footnotes (4)
- [F1]Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs"). No shares were sold.
- [F2]516,893 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power.
- [F3]Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
- [F4]This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 5,141 shares on January 31, 2023, vested as to 5,141 shares on January 31, 2024, vested as to 5,141 shares on January 31, 2025, and vested as to 5,142 shares on January 31, 2026, subject to the terms and conditions of the award.